These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 67089)

  • 1. C3 and C5-cleaving properdin enzymes formed on zymosan incubated with human serum: the decay and the regeneration of the enzymes.
    Fujita T; Takiuchi M; Matsumoto M; Nagaki K; Inai S
    Int Arch Allergy Appl Immunol; 1977; 53(4):303-9. PubMed ID: 67089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
    Medicus RG; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
    DiScipio RG
    Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular concept of the properdin pathway.
    Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The alternative pathway of complement activation.
    Götze O; Müller-Eberhard HJ
    Adv Immunol; 1976; 24():1-35. PubMed ID: 798473
    [No Abstract]   [Full Text] [Related]  

  • 6. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
    Brade V; Bentley C; Bitter-Suermann D; Hadding U
    Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activation mechanism of human complement system by immune precipitate formed with rabbit IgG antibody.
    Fujita T
    Microbiol Immunol; 1979; 23(10):1023-31. PubMed ID: 514094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.
    DiScipio RG
    Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C3 requirements for formation of alternative pathway C5 convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural modulation of the amplification phase of complement activation.
    Fearon DT; Daha MR; Weiler JM; Austen KF
    Transplant Rev; 1976; 32():12-25. PubMed ID: 62426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
    Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
    J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
    [No Abstract]   [Full Text] [Related]  

  • 12. The activation mechanism of the alternative pathway of the human complement system by the immune precipitate formed with F(ab')2 of rabbit IgG antibody: the generation of C3- and C5-cleaving enzymes on the immune precipitate.
    Fujita T; Takiuchi M; Iida K; Nagaki K; Inai S
    Immunochemistry; 1977 Jan; 14(1):25-30. PubMed ID: 849874
    [No Abstract]   [Full Text] [Related]  

  • 13. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
    Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
    J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
    Schreiber RD; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation of the C3-cleaving properdin enzyme on zymosan. Demonstration that factor D is replaceable by proteolytic enzymes.
    Brade V; Nicholson A; Bitter-Suermann D; Hadding U
    J Immunol; 1974 Dec; 113(6):1735-43. PubMed ID: 4279261
    [No Abstract]   [Full Text] [Related]  

  • 17. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
    Fearon DT; Austen KF; Ruddy S
    Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial: Glomerulonephritis, complement and C3NeF.
    Fearon DT
    N Engl J Med; 1976 Feb; 294(9):495-7. PubMed ID: 1246336
    [No Abstract]   [Full Text] [Related]  

  • 19. Activation of the complement and properdin systems in rheumatoid arthritis.
    Ruddy S; Austen KF
    Ann N Y Acad Sci; 1975 Jun; 256():96-104. PubMed ID: 1099964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of C5 convertase by epsilon amino caproic acid (EACA): a limiting factor in the generation of C5a anaphylatoxin.
    Vallota EH
    Immunology; 1978 Mar; 34(3):439-47. PubMed ID: 417019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.